Sabrina Welland1, Catherine Leyh2, Fabian Finkelmeier3, André Jefremow4,5, Kateryna Shmanko6, Maria A Gonzalez-Carmona7, Arne Kandulski8, Petia Jeliazkova9, Jan Best10, Thorben W Fründt11, Angela Djanani12, Maria Pangerl13, Andreas Maieron14, Richard Greil15, Christina Fricke14, Disorn Sookthai16, Rainer Günther13, Andreas Schmiderer12, Henning Wege11, Marino Venerito17, Ursula Ehmer9, Martina Müller8, Christian P Strassburg7, Arndt Weinmann6, Jürgen Siebler5,18, Oliver Waidmann3, Christian M Lange2, Anna Saborowski1, Arndt Vogel1. 1. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. 2. Department of Gastroenterology and Hepatology, University Hospital and University of Duisburg-Essen, Essen, Germany. 3. Department of Internal Medicine 1, Goethe-University Hospital Frankfurt, Frankfurt, Germany. 4. Department of Internal Medicine 1, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. 5. CCC-Erlangen EMN, Erlangen, Germany. 6. Department of Medicine I, University Medical Center Johannes Gutenberg University, Mainz, Germany. 7. Department of Internal Medicine 1, University Hospital of Bonn, Bonn, Germany. 8. Department of Internal Medicine I, Regensburg University Hospital, Regensburg, Germany. 9. Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. 10. Department of Internal Medicine, University Hospital Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany. 11. Department of Gastroenterology and Hepatology, University Medical Center, Hamburg, Germany. 12. Department of Gastroenterology, Hepatology and Endocrinology, University Hospital of Innsbruck, Innsbruck, Austria. 13. Department of Internal Medicine I, University Medical Center Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany. 14. Internal Medicine 2, Gastroenterology and Hepatology and Rheumatology, Karl Landsteiner University of Health Sciences, University Hospital of St. Pölten, St. Pölten, Austria. 15. Salzburg Cancer Research Institute, Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Erlangen, Germany. 16. Institut für Klinische Krebsforschung IKF GmbH, Frankfurt, Germany. 17. Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke-University Hospital Magdeburg, Magdeburg, Germany. 18. Deutsches Zentrum Immuntherapie (DZI), Erlangen, Germany.
Abstract
Background: Lenvatinib is approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The efficacy of lenvatinib in Caucasian real-world patients is insufficiently defined. The purpose of this study was to evaluate the efficacy of lenvatinib in a multi-center cohort (ELEVATOR) from Germany and Austria. Methods: A retrospective data analysis of 205 patients treated with first-line systemic lenvatinib at 14 different sites was conducted. Overall survival, progression free survival, overall response rate and adverse event rates were assessed and analyzed. Results: Patients receiving lenvatinib in the real-world setting reached a median overall survival of 12.8 months, which was comparable to the results reported from the REFLECT study. Median overall survival (mOS) and progression free survival (mPFS) was superior in those patients who met the inclusion criteria of the REFLECT study compared to patients who failed to meet the inclusion criteria (mOS 15.6 vs 10.2 months, HR 0.55, 95% CI 0.38-0.81, p=0.002; mPFS 8.1 vs 4.8 months HR 0.65, 95% CI 0.46-0.91, p=0.0015). For patients with an impaired liver function according to the Albumin-Bilirubin (ALBI) grade, or reduced ECOG performance status ≥2, survival was significantly shorter compared to patients with sustained liver function (ALBI grade 1) and good performance status (ECOG performance status 0), respectively (HR 1.69, 95% CI 1.07-2.66, p=0.023; HR 2.25, 95% CI 1.19-4.23, p=0.012). Additionally, macrovascular invasion (HR 1.55, 95% CI 1.02-2.37, p=0.041) and an AFP ≥200 ng/mL (HR 1.56, 95% CI 1.03-2.34, p=0.034) were confirmed as independent negative prognostic factors in our cohort of patients with advanced HCC. Conclusion: Overall, our data confirm the efficacy of lenvatinib as first-line treatment and did not reveal new or unexpected side effects in a large retrospective Caucasian real-world cohort, supporting the use of lenvatinib as meaningful alternative for patients that cannot be treated with IO-based combinations in first-line HCC.
Background: Lenvatinib is approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The efficacy of lenvatinib in Caucasian real-world patients is insufficiently defined. The purpose of this study was to evaluate the efficacy of lenvatinib in a multi-center cohort (ELEVATOR) from Germany and Austria. Methods: A retrospective data analysis of 205 patients treated with first-line systemic lenvatinib at 14 different sites was conducted. Overall survival, progression free survival, overall response rate and adverse event rates were assessed and analyzed. Results: Patients receiving lenvatinib in the real-world setting reached a median overall survival of 12.8 months, which was comparable to the results reported from the REFLECT study. Median overall survival (mOS) and progression free survival (mPFS) was superior in those patients who met the inclusion criteria of the REFLECT study compared to patients who failed to meet the inclusion criteria (mOS 15.6 vs 10.2 months, HR 0.55, 95% CI 0.38-0.81, p=0.002; mPFS 8.1 vs 4.8 months HR 0.65, 95% CI 0.46-0.91, p=0.0015). For patients with an impaired liver function according to the Albumin-Bilirubin (ALBI) grade, or reduced ECOG performance status ≥2, survival was significantly shorter compared to patients with sustained liver function (ALBI grade 1) and good performance status (ECOG performance status 0), respectively (HR 1.69, 95% CI 1.07-2.66, p=0.023; HR 2.25, 95% CI 1.19-4.23, p=0.012). Additionally, macrovascular invasion (HR 1.55, 95% CI 1.02-2.37, p=0.041) and an AFP ≥200 ng/mL (HR 1.56, 95% CI 1.03-2.34, p=0.034) were confirmed as independent negative prognostic factors in our cohort of patients with advanced HCC. Conclusion: Overall, our data confirm the efficacy of lenvatinib as first-line treatment and did not reveal new or unexpected side effects in a large retrospective Caucasian real-world cohort, supporting the use of lenvatinib as meaningful alternative for patients that cannot be treated with IO-based combinations in first-line HCC.
Authors: A Vogel; A Cervantes; I Chau; B Daniele; J M Llovet; T Meyer; J-C Nault; U Neumann; J Ricke; B Sangro; P Schirmacher; C Verslype; C J Zech; D Arnold; E Martinelli Journal: Ann Oncol Date: 2019-05-01 Impact factor: 32.976
Authors: A Jefremow; M Wiesmueller; R A Rouse; P Dietrich; A E Kremer; M J Waldner; M F Neurath; J Siebler Journal: J Physiol Pharmacol Date: 2021-02-08 Impact factor: 3.011
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Andrew X Zhu; Yoon-Koo Kang; Chia-Jui Yen; Richard S Finn; Peter R Galle; Josep M Llovet; Eric Assenat; Giovanni Brandi; Marc Pracht; Ho Yeong Lim; Kun-Ming Rau; Kenta Motomura; Izumi Ohno; Philippe Merle; Bruno Daniele; Dong Bok Shin; Guido Gerken; Christophe Borg; Jean-Baptiste Hiriart; Takuji Okusaka; Manabu Morimoto; Yanzhi Hsu; Paolo B Abada; Masatoshi Kudo Journal: Lancet Oncol Date: 2019-01-18 Impact factor: 41.316
Authors: Arndt Vogel; Lorenza Rimassa; Hui-Chan Sun; Ghassan K Abou-Alfa; Anthony El-Khoueiry; David J Pinato; Javier Sanchez Alvarez; Monica Daigl; Panos Orfanos; Michael Leibfried; Marie-Hélène Blanchet Zumofen; Vincent E Gaillard; Philippe Merle Journal: Liver Cancer Date: 2021-05-06 Impact factor: 11.740
Authors: Ângelo Z Mattos; Jose D Debes; Arndt Vogel; Marco Arrese; Xavier Revelo; Tales Henrique S Pase; Muriel Manica; Angelo A Mattos Journal: World J Gastroenterol Date: 2022-07-28 Impact factor: 5.374
Authors: Kurvi Patwala; David Stephen Prince; Yael Celermajer; Waafiqa Alam; Eldho Paul; Simone Irene Strasser; Geoffrey William McCaughan; Paul Gow; Siddharth Sood; Elise Murphy; Stuart Roberts; Elliot Freeman; Elizabeth Stratton; Scott Anthony Davison; Miriam Tania Levy; McCawley Clark-Dickson; Vi Nguyen; Sally Bell; Amanda Nicoll; Ashley Bloom; Alice Unah Lee; Marno Ryan; Jessica Howell; Zina Valaydon; Alexandra Mack; Ken Liu; Anouk Dev Journal: Hepatol Int Date: 2022-08-25 Impact factor: 9.029